CME Information

Target Audience

This activity is designed for specialists in gastroenterology, hepatology, and primary care.

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Describe how new developments in managing conditions of the upper and lower GI tract and liver diseases apply to current practice.
• Review current Barrett’s esophagus surveillance and ablation.
• Recommend appropriate screening and surveillance strategies to reduce the risk of colorectal cancer.
• Apply the most current strategies to evaluate and treat unexplained chronic abdominal pain, unexplained diarrhea, and unexplained GI bleeding.
• Employ a multimodal strategy that includes lifestyle changes, medication, endoscopy, and surgery to manage gastroesophageal reflux disease.
• Describe the current state-of-the-science in treatment for inflammatory bowel disease, including pharmacologic agents, dosage, and regimens designed to induce and maintain remission.
• Summarize new developments in medical treatment of viral hepatitis.
• Discuss the management of bile duct stones, probiotics in GI tract disease, and GI motility disorders.

Release Date: June 23, 2008.
Valid for credit through June 22, 2009.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Indiana University School of Medicine and Health Focus, Inc. Indiana University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Indiana University School of Medicine designates this educational activity for a maximum of 6.25 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

To receive credit, participants must view the presentation slides and listen to the audio recordings, and complete the posttest (passing score = 70% or higher) and evaluation form. Receive a CME certificate immediately by completing the posttest and evaluation form online.

Length of time to complete the activity: 6.25 hours.

 

Disclosure Information

Commercial Support

Indiana University School of Medicine and Health Focus, Inc. gratefully acknowledge the unrestricted educational grant provided by Salix Pharmaceuticals, Inc., and TAP Pharmaceutical Products, Inc.

Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. Dr. Chiorean reported that he has received speaker honorarium from Given, Inc., and consulting fees from Spirus, Inc. Dr. Kwo reported that he has received honoraria, grant support, and consulting fees from Schering, Vertex, Gilead, Novartis, and Roche. Dr. Rex reported that he has received speaker honoraria from TAP, CP Fleet, Salix, and Olympus; research support from Olympus, CB Fleet, Salix, MGI Pharma, and Given Imaging; and served on the Scientific Advisory Boards of Given Imaging, Avantis Medical Systems, CB Fleet, GI View, and American BioOptics. Drs. Fatima, Helper, Kahi, Kessler, Lehman, McHenry, and Wittles reported that they have no relationships to disclose.

The CME reviewer for this activity, Douglas Rex, MD, reported that he has received speaker honoraria from TAP, CP Fleet, Salix, and Olympus; research support from Olympus, CB Fleet, Salix, MGI Pharma, and Given Imaging; and served on the Scientific Advisory Boards of Given Imaging, Avantis Medical Systems, CB Fleet, GI View, and American BioOptics.

NOTICE: The Indiana University School of Medicine advises the participant that this CME activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.